236,765 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 236,765 shares of the company’s stock, valued at approximately $4,267,000.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. New Covenant Trust Company N.A. bought a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at about $30,000. UMB Bank n.a. boosted its position in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $48,000. Finally, Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $52,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.0 %

TEVA opened at $18.64 on Tuesday. Teva Pharmaceutical Industries Limited has a 12 month low of $8.55 and a 12 month high of $19.08. The business’s 50-day moving average price is $18.03 and its 200-day moving average price is $17.02. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Analyst Ratings Changes

Several analysts recently issued reports on TEVA shares. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Wednesday, July 10th. UBS Group upped their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays upped their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.